रैंकिंग पर वापस जाएं

ICU Medical, Inc. (ICUI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

49

मूल्य

$183.10

मार्केट कैप

$4.55B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

$2.16B

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$30M

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$92M

कुल इक्विटी

$2.12B

कुल देनदारियाँ

$1.93B

Current Ratio

2.43

Interest Coverage

0.87

Debt/EBITDA

5.28

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

General caseअधिक मूल्यांकित

Fair Value

$102.68

वर्तमान मूल्य

$183.10

Margin of Safety

-78.3%

Fair Value सीमा

$66.74 - $138.62

अनुमान विधियाँ

Analyst price target:$193.38
Discounted cash flow (DCF):$117.21
Earnings multiple (P/E):$22.75
Graham growth formula:$8.90
Earnings power value (EPV):$29.87
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$234.96
Revenue multiple:Not enough data to compute it
विश्लेषक सहमति:दृढ़ खरीदें (12B / 1H / 0S)
अंतिम Earnings सरप्राइज़:+21.43%

मूल्यांकन मेट्रिक्स

P/E Ratio

153.40

ROE

0.0%

P/B Ratio

2.12

P/FCF

29.87

Gross Margin

39.1%

ROIC

1.6%

लाभप्रदता Radar

Value Creation (Economic Moat)

ROIC

1.6%

WACC

8.5%

ROIC − WACC

-6.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental विश्लेषण मानदंड

पास (14)

  • Gross Margin 39.1%
  • P/FCF 29.87
  • P/B Ratio 2.12
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Revenue Growth 5Y 11.9%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 20.3%
  • Earnings Quality (OCF/NI) 7.86
  • Share Dilution 0.1%
  • Net Margin Trend 1.4% vs -1.6%
  • Piotroski F-Score 7/9

फेल (12)

  • EPS shows upward trend
  • EPS CAGR -19.56%
  • Price CAGR 2.18%
  • ROIC 1.6%
  • Operating Margin 3.3%
  • CapEx intensity
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.2%

अनुपलब्ध (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

मजबूत वित्तीय स्वास्थ्य

score
criteria

Earnings गुणवत्ता

7.86

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

0.1%

शेयर संख्या स्थिर है

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Vivek JainCEO & Chairman of the Board53
Mr. Daniel WoolsonPresident48
Mr. Brian Michael BonnellCFO & Treasurer51
Mr. Christian B. VoigtlanderChief Operating Officer57
Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer50
Ben SousaChief Information Officer-
Olivia BarrallVice President of Human Resources-

Audit जोखिम

5

बोर्ड जोखिम

4

मुआवजा जोखिम

4

शेयरधारक अधिकार जोखिम

5

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

Latest News

Recent headlines for ICUI, sourced from Markets Gazette.

No recent news for ICUI.
Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.